Category:

Dateline:

Public Company Information:

NASDAQ:

BIIB

US09062X1037

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen
Inc. (NASDAQ: BIIB) announced today that it will present at the
Goldman Sachs Healthcare CEOs Unscripted Conference. The webcast will be
live on Thursday, January 5, 2017 at 4:00p.m. ET. Additionally,
Bioverativ, the planned spin-off of Biogen’s hemophilia business, will
present as well. That webcast will be live on Thursday, January 5, 2017
at 3:15p.m. ET.

To access the live webcasts, please visit Biogen’s Investors section at www.biogen.com/investors.
An archived version of the webcast will be available for 14 days
following the presentation.

The planned spin-off of Bioverativ is expected to be completed on
February 1, 2017. Following the spin-off, Bioverativ will be an
independent, publicly-held global biotechnology company dedicated to
advancing the research, development and commercialization of innovative
therapies to address areas of serious unmet need for people with
hemophilia and other rare blood disorders.

About BiogenThrough cutting-edge science and medicine,
Biogen discovers, develops and delivers worldwide innovative therapies
for people living with serious neurological, autoimmune and rare
diseases. Founded in 1978, Biogen is one of the world’s oldest
independent biotechnology companies and patients worldwide benefit from
its leading multiple sclerosis and innovative hemophilia therapies. For
more information, please visit www.biogen.com.
Follow us on Twitter.